Citadel Advisors’s NKGen Biotech, Inc. Warrants NKGNW Stock Holding History

Citadel Advisors’s Portfolio NKGNW Stock Details NKGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-25,762	Closed	-$2.58K	–	15941
2024 Q4	$2.58K	Sell	25,762 -1,864	-7%	-$95	﹤0.01%	14069
2024 Q3	$1.95K	Buy	27,626 +1,100	+4%	+$98	﹤0.01%	13794
2024 Q2	$2.63K	Buy	26,526 +6,841	+35%	+$716	﹤0.01%	13665
2024 Q1	$3.15K	Buy	+19,685	New	+$2.24K	﹤0.01%	13940

Other funds holding NKGNW

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

Citadel Advisors's NKGNW Position: Q1 2025 in Review

Citadel Advisors sold out of NKGen Biotech, Inc. Warrants (NKGNW) in Q1 2025, closing a stake of 25,762 shares — an estimated $2.58K sold.

Citadel Advisors first reported a position in NKGNW in Q1 2024 and held it in 4 quarters. The position peaked at $3.15K in Q1 2024. 3 funds tracked by Wall St. Rank hold NKGNW as of Q1 2025.

Citadel Advisors reported no remaining NKGen Biotech, Inc. Warrants position as of Q1 2025 after selling out during the quarter.
Citadel Advisors sold 25,762 NKGen Biotech, Inc. Warrants shares in Q1 2025, an estimated $2.58K.
Citadel Advisors first reported a position in NKGen Biotech, Inc. Warrants in Q1 2024 and held it in 4 quarters.
Citadel Advisors's NKGen Biotech, Inc. Warrants position peaked at $3.15K in Q1 2024.
3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Warrants as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.